SLNSW-Bevacizumab and temozolomide in patients with fir...-TN_cdi_proquest_journals_2097516379

Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial

Full title: Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial

Author/creator: van den Bent, Martin J, Klein, Martin, Smits, Marion, Reijneveld, Jaap C, French, Pim J, Clement, Paul, de Vos, Filip Y F, Wick, Antje, Mulholland, Paul J, Taphoorn, Martin J B, Lewis, Joanne, Weller, Michael, Chinot, Olivier L, Kros, Johan M, de Heer, Iris, Verschuere, Tina, Coens, Corneel, Golfinopoulos, Vassilis, Gorlia, Thierry, Idbaih, Ahmed.

Call Numbers:

Record Identifier: TN_cdi_proquest_journals_2097516379

Language: English

Formats: Articles

Publishers: England: Elsevier Ltd

Permalink: https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2097516379

Articles

Articles

Export this record

Export selected records

  • Export to excel
  • Permalink

    • Export record to excel

    File type to download

    Beta version

    Record title

    Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial

    Record identifier

    TN_cdi_proquest_journals_2097516379

    Record permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2097516379

    Share

    Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial

    ACCESS
    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2097516379

    Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial

    Full title

    Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial

    Author / Creator

    van den Bent, Martin J ; Klein, Martin ; Smits, Marion ; Reijneveld, Jaap C ; French, Pim J ; Clement, Paul ; de Vos, Filip Y F ; Wick, Antje ; Mulholland, Paul J ; Taphoorn, Martin J B ; Lewis, Joanne ; Weller, Michael ; Chinot, Olivier L ; Kros, Johan M ; de Heer, Iris ; Verschuere, Tina ; Coens, Corneel ; Golfinopoulos, Vassilis ; Gorlia, Thierry ; Idbaih, Ahmed

    Publisher

    England: Elsevier Ltd

    Journal title

    The lancet oncology, 2018, Vol.19 (9), p.1170-1179

    Record Identifier

    TN_cdi_proquest_journals_2097516379

    Language

    English

    Formats

    Articles

    Publication information

    Publisher

    Subjects

    Subjects and topics

    Adult Analysis Angiogenesis Antineoplastic Agents, Alkylating - administration & dosage Antineoplastic Agents, Alkylating - adverse effects Antineoplastic Agents, Immunological - administration & dosage Antineoplastic Agents, Immunological - adverse effects Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Bevacizumab Bevacizumab - administration & dosage Bevacizumab - adverse effects Blood pressure Brain cancer Brain Neoplasms - drug therapy Brain Neoplasms - genetics Brain Neoplasms - mortality Brain Neoplasms - pathology Care and treatment Chemotherapy Chromosome Deletion Chromosomes, Human, Pair 1 Chromosomes, Human, Pair 19 Clinical trials Diseases Drug Administration Schedule Europe Fatigue Female Fistula Glioma Glioma - drug therapy Glioma - genetics Glioma - mortality Glioma - pathology Gliomas Hematology Hemorrhage Histology Humans Hypertension Immunotherapy Male Medical prognosis Middle Aged Monoclonal antibodies Nausea Neoplasm Grading Neoplasm Recurrence, Local Nervous system Neutropenia Patients Radiation therapy Relapse Studies Surgery Survival Targeted cancer therapy Temozolomide Temozolomide - administration & dosage Temozolomide - adverse effects Thrombocytopenia Time Factors Toxicity Treatment Outcome Tumors Ulcers

    More information

    — SCOPE AND CONTENTS

    Contents

    — ALTERNATIVE TITLES

    Full title

    — AUTHORS, ARTISTS AND CONTRIBUTORS

    Author / Creator

    Identifiers

    — PRIMARY IDENTIFIERS

    Record Identifier

    TN_cdi_proquest_journals_2097516379

    Permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2097516379

    — OTHER IDENTIFIERS

    ISSN

    E-ISSN

    DOI

    How to access this item

    Online

    1 item

    How to access?

    Login with a Library card

    Full text available >

    About resource >

    View in old catalogue

    Connecting people and collections